Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience

Imatinib treatment in metastatic or inoperable gastrointestinal stromal tumours (GIST) has shifted the paradigm of treatment of this disease. Successful clinical trials of imatinib led to rapid regulatory approval and, in England and Wales, National Institute for Health and Clinical Excellence (NICE...

Descripción completa

Detalles Bibliográficos
Autores principales: Azribi, F, Razak, ARA, Dildey, P, Adam, J, Wilsdon, J, Verrill, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223987/
https://www.ncbi.nlm.nih.gov/pubmed/22276023
http://dx.doi.org/10.3332/ecancer.2010.162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223987/
https://www.ncbi.nlm.nih.gov/pubmed/22276023
http://dx.doi.org/10.3332/ecancer.2010.162

Ejemplares similares